Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
ioa-244 save search
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Published: 2024-03-13 (Crawled : 11:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.69%
H: 1.1%
C: -0.71%
ion224 positive treatment results study
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
Published: 2022-12-08 (Crawled : 10:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 3.56%
H: 1.16%
C: -1.27%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: -0.11%
H: 0.71%
C: 0.24%
ioa-289 trial cancer pancreatic
iOnctura to Present at ASCO IOA-244 Showing Highly Promising Impact on Overall Survival for Patients With Metastatic and Refractory Uveal Melanoma
Published: 2022-05-27 (Crawled : 09:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 6.63%
H: 1.14%
C: -2.81%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 3.61%
H: 1.25%
C: 1.14%
ioa-244 melanoma asco
iOnctura to present at ASCO encouraging Phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kδ inhibitor, IOA-244
Published: 2022-05-17 (Crawled : 10:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 3.5%
H: 5.36%
C: -0.64%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 3.3%
H: 0.04%
C: 0.0%
ioa-244 asco
iOnctura to Present Preclinical Data on its Clinical Stage Autotaxin Inhibitor, IOA-289, at AACR
Published: 2022-03-09 (Crawled : 10:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 4.92%
H: 3.98%
C: -1.55%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 6.63%
H: 2.85%
C: 0.87%
ioa-289 xin preclinical pre-clinical
iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor Study of PI3Kδ Inhibitor IOA-244 Presented at ESMO-IO
Published: 2021-12-09 (Crawled : 08:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -6.26%
H: 4.62%
C: 0.72%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: -2.24%
H: 0.01%
C: -0.69%
ioa-244
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies
Published: 2021-12-09 (Crawled : 08:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -6.26%
H: 4.62%
C: 0.72%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: -2.24%
H: 0.01%
C: -0.69%
ioa-289 xin positive cancer pancreatic
iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December 2021
Published: 2021-11-23 (Crawled : 09:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -0.6%
H: 0.0%
C: -0.51%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 0.03%
H: 0.49%
C: 0.49%
preclinical pre-clinical
iOnctura Presents Compelling Preclinical Data on its Clinical Stage Autotaxin Inhibitor IOA-289 at SITC
Published: 2021-11-12 (Crawled : 22:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 1.94%
H: 0.43%
C: -1.24%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 2.0%
H: 0.84%
C: 0.66%
preclinical pre-clinical
iOnctura Clinical Expansion Positions Lead PI3Kδ Inhibitor IOA-244 for Potential Registration Studies in Metastatic Uveal Melanoma
Published: 2021-11-08 (Crawled : 10:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -0.16%
H: 0.52%
C: 0.28%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 1.09%
H: 0.21%
C: -0.16%
potential expansion positive
iOnctura to Share Preclinical Data on IOA-289 at SITC in November 2021
Published: 2021-11-02 (Crawled : 10:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -0.02%
H: 0.0%
C: -1.29%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: -1.57%
H: 0.11%
C: -0.08%
preclinical pre-clinical
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.